NovaBay Pharmaceuticals Awarded 1st Place for Outstanding Scientific Presentation at The Simon Foundation for Continence Conference

EMERYVILLE, CA – April 14, 2011 -- NovaBay Pharmaceuticals, Inc. (NYSE Amex: NBY) has won the 1st Place Award for Outstanding Poster Presentation at the 2011 conference of The Simon Foundation for Continence, “Innovating for Continence: The Engineering Challenge,” which was held in Chicago on April 11-13.

The award-winning poster, “NVC-422 Prevents Urinary Catheter Blockage and Encrustation,” reports that NovaBay’s lead Aganocide® compound has been observed to reduce P. mirabilis bacteria, urinary pH, and crystalline encrustation in lab models of catheterized bladders. A NovaBay team conducted the research to address the challenge faced by patients with long-term indwelling bladder catheters, who often face bacterial colonization causing encrustation and subsequent catheter blockage which often lead to incontinence and serious infections. Among the criteria considered in the selection process were contribution to the theme of the conference, significance of the research, framing of the incontinence problem and support for the scientific conclusions reached.

NovaBay’s poster was one of 27 posters presented at the conference by companies that included Kimberly-Clark Corp., Medtronic Inc. and Uroplasty Inc., as well as academic institutions and facilities based in the United States, United Kingdom, Argentina and Korea. The conference attracts leading scientists from several disciplines, a variety of healthcare providers, academics, and executives from companies in the incontinence industry.